PARP inhibitors represent an exciting new class of anticancer agents and are currently being evaluating in phase III for a number of different indications.
John F. Hilton, MD
Advertisement
Articles by John F. Hilton, MD
Advertisement
Latest Updated Articles
PARP Inhibitors for Breast and Ovarian CancersNovember 26th 2014
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Breakthrough Therapy Designation to 64Cu-SAR-bisPSMA for PSMA PET in Biochemically Recurrent Prostate Cancer
2
Detalimogene Responses Improve With Longer Follow-Up in BCG-Unresponsive NMIBC Ahead of BLA Submission
3
Combination Therapy Overcomes Treatment Resistance in Breast Cancer Models
4
Dr Wander on the Evolving First-Line and Post–T-DXd Landscape in HER2+ Metastatic Breast Cancer
5